• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Blog
  • News & Events
  • Videos
main-logo-small

Compliance Architects

Consulting Technology Outsourcing

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

As someone with many years of experience working in and around FDA-regulated manufacturing operations, a recent LinkedIn post (March 2018) entitled “Why QUALITY Needs to STOP Working on COMPLIANCE” has really rankled me.   Unfortunately, this is not the first time this topic has been discussed.  There are frequent speakers these days berating “compliance” in favor of “quality.”

Despite how de rigueur it has become to embrace this premise, I remain unconvinced.

In fact, a discussion about Quality and Compliance is not a competition or an either/or proposition.    I believe strongly that it’s a dangerous message to refer to compliance as a non-value-added activity (an expense as the article referenced above stated) while referring to quality as some abstract panacea that magically occurs from some creative or innovative activity that is not being done because of the focus on “the bad compliance activities.”

I submit that this characterization is a gross oversimplification.

Medical Devices & PharmaceuticalsWhat IS QUALITY if not the activity that ensures conformance to defined requirements and expectations?  What IS COMPLIANCE if not the activity that ensures conformance to defined requirements and expectations?  The only difference is that, with respect to Quality, it’s patient, customer, and market-centric requirements and expectations that ensure therapeutic and commercial success.  With respect to Compliance, it’s third-party regulator and NGO requirements and expectations that are in place to ensure a baseline-level of performance, for quality – whether the company wants to or not.   My long experience has been that those organizations that do the best jobs with defining quality requirements and expectations – and driving relentlessly to meeting them consistently – are the same organizations that achieve the best outcomes with compliance.

In my opinion, the focus for FDA-regulated industry shouldn’t be on devaluing one discipline versus the other.  On the contrary, the focus should be on doing rigorous definition of the requirements and expectations for both Quality and Compliance;  aligning these efforts where commonality of approach exists; and ensuring sufficient systems, practices, and people exist to consistently carry out the activities that achieve both sets of requirements and expectations.

Quality is important.   Compliance is important.  Let’s stop bashing compliance.   Let’s focus on doing both disciplines better.

 

Filed Under: Achieving Compliance

Primary Sidebar

Sign Up To Our Newsletter

You May Also Like

FDA Quality Agreements

What Should Companies Concentrate On When Partnering with CMOs and CDMOs?

The CDMO and CMO relationships and the whole kind of business dynamic is critically important to the life sciences space. And particularly now with what

How Does Compliance Architects® Help the Biopharmaceutical Industry Achieve Its Goals?

I think the fundamental principle for all regulated industry whether it be biopharmaceuticals, medical devices, is that scientific concepts do not result in products for
Biopharmaceutical risk

How Has Risk Changed for the Biopharmaceutical Industry in Light of Recent Events?

Risk is still an important issue, and the fundamental premise is that there is so much to do. The science is so complex. The regulatory

Footer

Compliance Architects®

  • Contact Us
  • (888) 734-9778
  • info@compliancearchitects.com

Quick Links

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

Our Services

  • Inspection Readiness & Enforcement
  • FDA Quality Consulting – Systems and Training
  • Quality Assurance and Engineering
  • Corporate Compliance and Litigation Services
  • FDA Regulatory Consultants – Due Diligence
  • Quality, Compliance, Regulatory & Operations’ Staffing Services

Proprietary Solutions

  • Writing for Compliance®
  • Quality Pulse®
  • CRPN Quality Roadmap®

© 2009-2022 Compliance Architects Holdings LLC – used by permission. All copyrights, trademarks and other intellectual property are the property of Compliance Architects Holdings LLC and are used by permission.

  • Debarment Certification Statement
  • Privacy Policy
  • Terms of Use

Contact Us Today